EP1003516A4 - Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires - Google Patents

Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires

Info

Publication number
EP1003516A4
EP1003516A4 EP99935334A EP99935334A EP1003516A4 EP 1003516 A4 EP1003516 A4 EP 1003516A4 EP 99935334 A EP99935334 A EP 99935334A EP 99935334 A EP99935334 A EP 99935334A EP 1003516 A4 EP1003516 A4 EP 1003516A4
Authority
EP
European Patent Office
Prior art keywords
administration
side effects
cancer treatment
reduced side
camptothecin compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99935334A
Other languages
German (de)
English (en)
Other versions
EP1003516A1 (fr
Inventor
Bernard Bouscarel
Kunihiko Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Washington University
Original Assignee
George Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Washington University filed Critical George Washington University
Publication of EP1003516A1 publication Critical patent/EP1003516A1/fr
Publication of EP1003516A4 publication Critical patent/EP1003516A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP99935334A 1998-06-18 1999-06-18 Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires Withdrawn EP1003516A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8978198P 1998-06-18 1998-06-18
US89781P 1998-06-18
PCT/US1999/013906 WO1999065493A1 (fr) 1998-06-18 1999-06-18 Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires

Publications (2)

Publication Number Publication Date
EP1003516A1 EP1003516A1 (fr) 2000-05-31
EP1003516A4 true EP1003516A4 (fr) 2006-07-12

Family

ID=22219554

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99935334A Withdrawn EP1003516A4 (fr) 1998-06-18 1999-06-18 Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires

Country Status (7)

Country Link
EP (1) EP1003516A4 (fr)
JP (1) JP2002518332A (fr)
CN (1) CN1325305A (fr)
AU (1) AU764370B2 (fr)
CA (1) CA2300892A1 (fr)
IL (1) IL134592A0 (fr)
WO (1) WO1999065493A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300892A1 (fr) * 1998-06-18 1999-12-23 The George Washington University Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires
DE60030283T2 (de) 1999-05-17 2007-09-20 Cancer Research Ventures Ltd. Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
CA2295429A1 (fr) * 2000-01-06 2001-07-06 Michael Michael Traitement ou prevention de la diarrhee
US7691872B2 (en) * 2001-03-20 2010-04-06 University Of Kentucky Research Foundation Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
AU2007232206B2 (en) 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
JP5919593B2 (ja) * 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
CN106999468B (zh) * 2014-10-21 2019-10-25 强普生技股份有限公司 熊脱氧胆酸和水飞蓟素改进cpt-11疗效和毒性的制药用途
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN107281462A (zh) * 2017-08-21 2017-10-24 滨州医学院 沙奎拉韦减轻伊立替康毒性的医药新用途
US11000540B1 (en) * 2019-11-22 2021-05-11 Al Siamon Treatment for reducing adverse events including chemotherapy discomfort and other conditions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
JPH02270822A (ja) * 1989-02-07 1990-11-05 Duphar Internatl Res Bv 経口再水和溶液調製用の発泡製品
EP0524579A1 (fr) * 1991-07-22 1993-01-27 Bristol-Myers Squibb Company Formulations orales dosées et améliorées de dideoxy purine nucléosides
WO1994028911A1 (fr) * 1993-06-08 1994-12-22 Farmaceutisk Laboratorium Ferring A/S COMPOSITIONS UTILISEES DANS LA REGULATION DE VALEURS DE pH SUBNORMALES DES VOIES INTESTINALES ET DANS LE TRAITEMENT DES MALADIES DE L'INTESTIN
WO1996006635A1 (fr) * 1994-08-31 1996-03-07 Cortecs Limited Compositions pharmaceutiques contenant un sel biliaire et un tampon destinees a accroitre la biodisponibilite d'un compose actif
WO1996011005A2 (fr) * 1994-10-06 1996-04-18 Atlas Leon T Utilisation de camptothecine ou de derives de camptothecine dans la fabrication d'un medicament destine au traitement de maladies virales
JPH10201821A (ja) * 1997-01-23 1998-08-04 Material Eng Tech Lab Inc 医療用容器

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
CA2300892A1 (fr) * 1998-06-18 1999-12-23 The George Washington University Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
JPH02270822A (ja) * 1989-02-07 1990-11-05 Duphar Internatl Res Bv 経口再水和溶液調製用の発泡製品
EP0524579A1 (fr) * 1991-07-22 1993-01-27 Bristol-Myers Squibb Company Formulations orales dosées et améliorées de dideoxy purine nucléosides
WO1994028911A1 (fr) * 1993-06-08 1994-12-22 Farmaceutisk Laboratorium Ferring A/S COMPOSITIONS UTILISEES DANS LA REGULATION DE VALEURS DE pH SUBNORMALES DES VOIES INTESTINALES ET DANS LE TRAITEMENT DES MALADIES DE L'INTESTIN
WO1996006635A1 (fr) * 1994-08-31 1996-03-07 Cortecs Limited Compositions pharmaceutiques contenant un sel biliaire et un tampon destinees a accroitre la biodisponibilite d'un compose actif
WO1996011005A2 (fr) * 1994-10-06 1996-04-18 Atlas Leon T Utilisation de camptothecine ou de derives de camptothecine dans la fabrication d'un medicament destine au traitement de maladies virales
JPH10201821A (ja) * 1997-01-23 1998-08-04 Material Eng Tech Lab Inc 医療用容器

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ARAKI E ET AL: "RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 84, no. 6, June 1993 (1993-06-01), pages 697 - 702, XP008059720, ISSN: 0910-5050 *
ATSUMI R ET AL: "METABOLISM OF IRINOTECAN TO SN-38 IN A TISSUE-ISOLATED TUMOR MODEL", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 18, no. 7, July 1995 (1995-07-01), pages 1024 - 1026, XP008059867, ISSN: 0918-6158 *
HERBEN V M M ET AL: "CLINICAL PHARMACOKINETICS OF TOPOTECAN", CLINICAL PHARMACOKINETICS, LEA & FEBIGER, PHILADELPHIA, PA, US, vol. 31, no. 2, 1996, pages 85 - 102, XP000874360 *
KOBAYASGI K. ET AL.: "Reduced Irinotecan-induced side-effects by the oral Alkalinization", PROC. AM. SOC. CLIN. ONCOL., vol. 18, no. 35, 15 May 1999 (1999-05-15), 35th annual meeting of ASCO, pages 492A, XP002370825 *
KOBAYASHI K ET AL: "UPTAKE MECHANISM OF IRINOTECAN (CPT-11) AND ITS METABOLITE (SN-38) BY HAMSTER INTESTINAL CELLS", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 114, no. 4, 15 April 1998 (1998-04-15), pages A626 - A627, XP008059718, ISSN: 0016-5085 *
MATSUZAKI Y ET AL: "CELLULAR UPTAKE AND TOXICITY OF IRINOTECAN AND ITS ACTIVE METABOLITE, SN-38 IN HAMSTER INTESTINE AND HUMAN COLON CANCER CELLS", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 116, no. 4, PART 2, April 1999 (1999-04-01), pages A906,ABSTRNOG3940, XP008059942, ISSN: 0016-5085 *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 13 30 November 1998 (1998-11-30) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 06 31 March 1999 (1999-03-31) *
SCHELLENS J H M ET AL: "PHARMACOKINETICS (PK), CLINICAL PHARMACODYNAMICS (PD), AND SAFETY OF CHRONIC ORAL TOPOTECAN (T), IN A PHASE STUDY", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 31, no. 6, 1 November 1995 (1995-11-01), pages S192,ABSTRNO926, XP008059770, ISSN: 0959-8049 *
SCOTT D O ET AL: "URINARY AND BILIARY DISPOSITION OF THE LACTONE AND CARBOXYLATE FORMS OF 20(S)-CAMPTOTHECIN IN RATS", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 22, no. 3, May 1994 (1994-05-01), pages 438 - 442, XP008059680, ISSN: 0090-9556 *
See also references of WO9965493A1 *

Also Published As

Publication number Publication date
EP1003516A1 (fr) 2000-05-31
CA2300892A1 (fr) 1999-12-23
CN1325305A (zh) 2001-12-05
WO1999065493A1 (fr) 1999-12-23
IL134592A0 (en) 2001-04-30
AU764370B2 (en) 2003-08-14
JP2002518332A (ja) 2002-06-25
WO1999065493A9 (fr) 2000-03-23
AU5083399A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
DE60007257D1 (de) Verfahren zur Herstellung von Cucurbituril Derivaten
DE69834437D1 (de) Verfahren zur Herstellung von Fenofibrathaltigen Arzneizusammensetzungen mit erhöhter Bioverfügbarkeit
DE69926686D1 (de) Vorrichtung zur Verabreichung von hochkonzentrierten NO Pulsen
ATE389401T1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
EP1438054A4 (fr) Procedes et compositions pour traiter des flavivirus et des pestivirus au moyen d'un nucleoside modifie en position 4'
DE59901908D1 (de) Verfahren zur Herstellung von beschichteten festen Dosierungsformen
DE69913071D1 (de) Verfahren zur Herstellung von veresterten Verbindungen
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
ATE309257T1 (de) Verfahren zur herstellung von amin-platin- komplexen
DK1250152T3 (da) Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
DE69838770D1 (de) Verfahren zur Herstellung elektrolumineszierender Vorrichtungen
DE69912254D1 (de) Kosmetisches verfahren zur hautbehandlung
DE60019747D1 (de) Verfahren zur herstellung von fluorolefinen
EP1003516A4 (fr) Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires
DE69834613D1 (de) Halbleiterbauelement und verfahren zur dessen herstellung
DE60024372D1 (de) Verfahren zur Herstellung von Tetraorganooxysilanen
DE19981703T1 (de) Verfahren zur Herstellung von Metallocenkomplexen
DE69823275T2 (de) Verfahren zur Herstellung von Vorrichtungen zur kontrollierten Freisetzung von Arzneimitteln
DE60031231D1 (de) Verfahren zur Herstellung von 2-Alkyl-4-Isothiazolin-3-onen
DE69902071D1 (de) Verfahren zur Herstellung von 2-substituierten Pyridinen
DE60019763D1 (de) Verfahren zur herstellung von thiazolderivaten
DE60004119D1 (de) Verfahren zur Herstellung von Pentaacetyl-beta-D-Glucopyranose
EP1112250A4 (fr) Composes therapeutiques et methodes afferentes
DE50006598D1 (de) VERFAHREN ZUR HERSTELLUNG VON CYCLO-(Asp-DPhe-NMeVal-Arg-Gly)
DE50003603D1 (de) Verfahren zur Herstellung von Bistrifluormethylbenzylaminen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB NL

17P Request for examination filed

Effective date: 20000320

A4 Supplementary search report drawn up and despatched

Effective date: 20060612

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060912